Retatrutide: How It Works, What It's Studied For & Safety
Retatrutide is an investigational triple agonist of the GLP-1, GIP, and glucagon receptors in late-stage clinical development for chronic weight management and related metabolic conditions. Clinicians consider it for chronic weight management in adults with obesity (Phase 3, TRIUMPH program). Not FDA-approved; dispensed by Wells Pharmacy Network only after a clinician evaluation.
Also known as: LY3437943
How does Retatrutide work?
Retatrutide is a single peptide engineered to bind GLP-1, GIP, and glucagon receptors simultaneously. The triple-incretin engagement is studied for additive effects on insulin signalling, satiety, gastric emptying, and energy expenditure beyond dual-incretin agonists.
What is Retatrutide studied for?
- Chronic weight management in adults with obesity (Phase 3, TRIUMPH program)
- Glycemic control in type 2 diabetes (Phase 2/3 research)
- Metabolic dysfunction-associated steatotic liver disease (MASLD) and related cardiometabolic endpoints
How is Retatrutide taken?
Investigational once-weekly subcutaneous injection. Not FDA-approved. Not commercially available outside of clinical trials and clinician-directed research contexts.
Is Retatrutide FDA-approved? Is it safe?
Not FDA-approved for the prevention, treatment, or cure of any condition. Used inside research-informed, clinician-directed protocols only. Reported effects in trials are predominantly GI (nausea, vomiting, diarrhea), most pronounced during dose escalation. Long-term safety in real-world populations has not yet been established. Compounded prescription-only preparations are dispensed by Wells Pharmacy Network. Eligibility is decided by a licensed clinician based on intake and labs, not by checkout. Compounded products on this site are not FDA-approved and are not generic equivalents of any branded medication.
In the Regen Therapy catalog
This compound does not currently appear in an active Regen Therapy protocol. Browse the full catalog for adjacent options.
What does the research say about Retatrutide?
Phase 2 obesity and diabetes trials reported the largest mean body-weight reductions seen with any incretin-based agent to date; the Phase 3 TRIUMPH program in obesity is ongoing.
Citations & further reading
Considering Retatrutide as part of a protocol?
Browse Regen Therapy's catalog or start a clinician evaluation. Every prescription is reviewed by a licensed clinician and dispensed by Wells Pharmacy Network.
Browse the catalog →